Antiviral curative effects of tenofovir and entecavir in treatment of aged patients with chronic hepatitis B and their regulation on inflammation factors / 吉林大学学报(医学版)

ABSTRACT

Objective: To compare the clinical efficacies of tenofovir (TI)F) and entecavir (ETV) in the treatment of the aged patients with chronic hepatitis B (CHB) and their regulation on the inflammation factors, and to provide basis for their clinical application. Methods: A total of 93 aged patients with CHB were selected and randomly divided into TDF group (71= 48) and ETV group (71= 45). And the patients were treated with TDF (300 mg time. 1 time • d-1 ) and ETV (0.5 mg time. 1 time • d-1 ); the patients in uvo groups were observed for continuous 48 weeks. The levels of serum hepatitis B virus-deoxyribonucleic acid (HBV-DNA). glutamic pyruvic transaminase (ALT), and tumor necrosis factor a (TNF-a), interleukin-10 (IL-10), the ALT recovery rates, the HBV-DNA negative conversion rates, and the HBeAg negative rates of the patients in uvo groups were detected before treatment and 4, 12, 24, 36 and 48 weeks after treatment, respectively. Results: Compared with before treatment, the levels of serum HBV-DNA and ALT of the patients in uvo groups after treatment were decreased (P0. 05). Conclusion: Both TDF and ETV could be used to treat the aged patients with CHB. TDF has earlier antiviral effect and can bring quick recovery in liver function with lighter inflammatory reaction. TDF is an ideal antiviral drug for clinical treatment.